Oblidox CV 325 Tablet is a combination antibiotic formulation containing Cefpodoxime Proxetil 200 mg and Clavulanic Acid 125 mg, designed for the treatment of various bacterial infections. Cefpodoxime Proxetil, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effectively targeting both Gram-positive and Gram-negative organisms. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefpodoxime by preventing the degradation of the antibiotic by beta-lactamase enzymes produced by resistant bacteria. This synergistic combination is indicated for the management of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media caused by susceptible strains. Oblidox CV 325 Tablet is administered orally and is generally well-tolerated, with common adverse effects including gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Caution is advised in patients with a history of hypersensitivity to cephalosporins or penicillins. Dosage adjustments may be necessary in patients with renal impairment. The use of Oblidox CV 325 Tablet should be guided by culture and sensitivity results to ensure optimal therapeutic outcomes and to minimize the development of antibiotic resistance.